Literature DB >> 2686173

Long-term anticoagulation. Indications and management.

B M Stults, W H Dere, T H Caine.   

Abstract

Each year half a million persons in the United States receive long-term anticoagulant therapy to prevent venous and arterial thromboembolism. Unfortunately, the relative benefits and risks of anticoagulant therapy have not been adequately quantified for many thromboembolic disorders, and the decisions as to whether, for how long, and how intensely to administer anticoagulation are often complex and controversial. Several expert panels have published recommendations for anticoagulant therapy for different thromboembolic disorders; the primary area of disagreement among these panels concerns the optimal intensity of anticoagulation. Recent research and analytic reviews have helped to clarify both the risk factors for and the appropriate diagnostic evaluation of anticoagulant-induced hemorrhage. Clinicians must be aware of the nonhemorrhagic complications of anticoagulant therapy, particularly during pregnancy. The administration of anticoagulants is difficult both in relation to dosing and long-term monitoring. Knowledge of the pharmacology of the anticoagulants, an organized approach to ongoing monitoring, and thorough patient education may facilitate the safe and effective use of these drugs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2686173      PMCID: PMC1026829     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  140 in total

1.  Therapeutic quality control leading to further clinical assessment of oral anticoagulation.

Authors:  B M Duxbury
Journal:  Acta Haematol       Date:  1986       Impact factor: 2.195

2.  Frequency of attendance at anticoagulant clinics.

Authors:  M R Howard; D W Milligan
Journal:  Acta Haematol       Date:  1986       Impact factor: 2.195

3.  Clinical and echocardiographic correlates of systemic embolization in nonrheumatic atrial fibrillation.

Authors:  I Wiener
Journal:  Am J Cardiol       Date:  1987-01-01       Impact factor: 2.778

4.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; J Hirsh; R M Jay; J R Leclerc; W H Geerts; D Rosenbloom; D L Sackett; C Anderson; L Harrison
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

5.  On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.

Authors:  B Karlson; B Leijd; K Hellström
Journal:  Acta Med Scand       Date:  1986

Review 6.  Thrombosis and embolism from cardiac chambers and infected valves.

Authors:  P C Adams; M Cohen; J H Chesebro; V Fuster
Journal:  J Am Coll Cardiol       Date:  1986-12       Impact factor: 24.094

Review 7.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

8.  Pulmonary embolism from a venous thrombus located below the knee.

Authors:  T Bartter; H M Hollingsworth; R S Irwin; J A Bianco; D J Frid; J E Dalen
Journal:  Arch Intern Med       Date:  1987-02

9.  Cholestatic hepatic injury related to warfarin exposure.

Authors:  E Adler; S B Benjamin; H J Zimmerman
Journal:  Arch Intern Med       Date:  1986-09

10.  Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.

Authors:  A Gallus; J Jackaman; J Tillett; W Mills; A Wycherley
Journal:  Lancet       Date:  1986-12-06       Impact factor: 79.321

View more
  2 in total

1.  Low-Dose Vitamin K Therapy in Excessively Anticoagulated Patients: A Dose-Finding Study.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Vitamin K epoxide reductase regulation of androgen receptor activity.

Authors:  Ben Yi Tew; Teresa B Hong; Maya Otto-Duessel; Catherine Elix; Egbert Castro; Miaoling He; Xiwei Wu; Sumanta K Pal; Markus Kalkum; Jeremy O Jones
Journal:  Oncotarget       Date:  2017-02-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.